Skip to main content
New Year’s Sale — Build a balanced news diet with 40% off Vantage
Get Started
SubscribeLogin
Published • loading... • Updated

Acrivon Therapeutics Spotlights ACR368 Endometrial Cancer Data, Adds Serous Arm 3 and FDA Phase 3 Plan

Summary by marketbeat.com
Acrivon Therapeutics (NASDAQ:ACRV) highlighted new interim clinical results for its lead program ACR368 in endometrial cancer and provided early clinical and preclinical updates across its pipeline during a conference call hosted by CFO and Head of Investor Relations Adam Levy. AP3 platform positio

1 Articles

marketbeat.commarketbeat.com
Center

Acrivon Therapeutics Spotlights ACR368 Endometrial Cancer Data, Adds Serous Arm 3 and FDA Phase 3 Plan

Acrivon Therapeutics (NASDAQ:ACRV) highlighted new interim clinical results for its lead program ACR368 in endometrial cancer and provided early clinical and preclinical updates across its pipeline during a conference call hosted by CFO and Head of Investor Relations Adam Levy. AP3 platform positio

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

marketbeat.com broke the news in on Thursday, January 8, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

CFO icon

CFO

FDA icon

FDA

Cancer icon

Cancer

Health & Medicine icon

Health & Medicine

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal